CC

Commodore Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 73.3%
This Quarter Est. Return
1 Year Est. Return
+73.3%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.42B
AUM Growth
+$59.6M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
38
New
Increased
Reduced
Closed

Top Buys

1
+$59.4M
2
+$57.2M
3
+$46.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$32.7M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$21.9M

Top Sells

1
+$62.3M
2
+$49.9M
3
+$47.3M
4
SLNO icon
Soleno Therapeutics
SLNO
+$45.2M
5
VERA icon
Vera Therapeutics
VERA
+$41.5M

Sector Composition

1 Healthcare 99.44%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
26
Apogee Therapeutics
APGE
$3.64B
$12.6M 0.89%
290,000
IKT icon
27
Inhibikase Therapeutics
IKT
$114M
$10.5M 0.74%
5,397,488
+53,056
PCSC
28
Perceptive Capital Solutions
PCSC
$7.96M 0.56%
750,000
TNGX icon
29
Tango Therapeutics
TNGX
$838M
$7.68M 0.54%
+1,500,000
CBIO
30
Crescent Biopharma
CBIO
$215M
$7.32M 0.52%
+453,686
NGNE icon
31
Neurogene
NGNE
$410M
$6.4M 0.45%
427,866
-497,134
VTGN icon
32
VistaGen Therapeutics
VTGN
$128M
$3.15M 0.22%
1,575,000
AVTX icon
33
Avalo Therapeutics
AVTX
$319M
$2.41M 0.17%
483,000
CELC icon
34
Celcuity
CELC
$2.99B
– –
-695,650
CRDF icon
35
Cardiff Oncology
CRDF
$147M
– –
-5,384,616
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.21B
– –
-2,000,000
PCVX icon
37
Vaxcyte
PCVX
$5.4B
– –
-1,650,000
SLDB icon
38
Solid Biosciences
SLDB
$430M
– –
-5,825,000
1
2